Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do - Healthcare Research Tue, 27 Jun 2017 6:08:43 Advances in Healthcare, Desalination, and Waste Heat Recovery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-4C-00-00 This edition of the Inside R&D TOE depicts developments associated with innovations in healthcare, desalination, and waste heat recovery. The TOE also emphasizes on developments in the fields of stem cells and alternative antibiotics. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Stem cells, sleep therapy, alternative antibiotics, solar desalination Fri, 23 Jun 2017 00:00:00 +0100 Blockchain Technology in Global Healthcare, 2017 2025 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1DB-01-00-00-00 Blockchain technology, with its ubiquitous security infrastructure for seamless health data exchange, holds potential to eliminate the burden and cost of health data reconciliation and facilitate interoperability. Emerging blockchain systems promise to unlock new economic advantages by disintermediating high-cost gatekeepers and automating transactional services across healthcare workflows (e.g., claim adjudication, billing management, RCM, drug supply chain). Increasing pricing pressure to decrease healthcare cost globally and digitization of care delivery models are transitioning the industry toward a much-anticipated personalized treatment paradigm. With these health systems, payers and drug and device manufacturers equally urgently require a secure connected health IT ecosystem to manage healthcare data and promote value-based care. At its core, blockchain offers the potential of a shared platform that decentralizes health data, ensuring access control, authenticity, and integrity of protected health information. Further, the blockchain-based distributed network consensus with cryptography techniques provides an additional layer of trust to minimize cybersecurity threats for healthcare IT systems. This never-before blockchain-based trusted workflow with a single source of truth presents the healthcare industry with radical new possibilities for outcome-based care delivery and reimbursement models. Despite the hype around blockchain, for many people (across different industries), the blockchain concept remains difficult to grasp which makes it one of the most misunderstood technologies of 2017. Blockchain technology may not be the panacea for healthcare industry challenges but it holds the potential to save billions of dollars by optimizing current workflows and the disintermediation of some high-cost gatekeepers. Research Scope The research service analyzes the key trends and developments around blockchain technology and captures the essential building blocks for implementing a healthcare-focused blockchain ecosystem in the next 5 10 years. Differentiating the hype from reality, the study discusses blockchain technology s most potential applications in some of the pressing needs of the healthcare industry such as health data interoperability, cybersecurity, insurance fraud management, and drug supply chain provenance. The study also provides a global flavor around blockchain technology deployment and discusses current adoption trends across major healthcare-focused use cases such as the adoption timeline, growth opportunities, implementation challenges, government and commercial initiatives, select collaboration or deals, and the key companies and consortiums to watch. Finally, the study provides strategic imperatives and recommended business models to foster healthcare-focused blockchain ecosystem partnerships for future implementation on a large scale across healthcare use cases. Key Questions This Study Will Answer What is blockchain technology and what are its implications for the healthcare industry? Who are the key stakeholders in the healthcare blockchain ecosystem? What is the convergence potential for blockchain with emerging healthcare technologies? What are the most promising application areas of blockchain for the healthcare industry? What are the adoption and growth trends for these use cases? Which are the leading companies with healthcare-deployable blockchain solutions? What are the possible business models for blockchain technology deployment in healthcare applications? What are the challenges for implementing blockchain in healthcare? Fri, 23 Jun 2017 00:00:00 +0100 Recent Advances in Cancer Therapy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4C-00-00 This edition of the Genetic Technology TOE depicts trends across cancer therapy. Stem cell therapies, check-point inhibitors, and other novel biomarkers are illustrated through the most recent innovations in immuno-oncology. A summary of industry-funded clinical trials for stem cell therapy in blood cancers is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Umbilical cord stem cells, check-point inhibitors, immuno-oncology, immune activation, cancer therapy, immunotherapy, anti-inflammatory functions, predictive biomarkers, precision oncology Fri, 23 Jun 2017 00:00:00 +0100 US Endoscope Repair Solutions Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K183-01-00-00-00 The study covers current and future market trends, drivers, challenges, and key opportunities in US endoscope repair market. It analyzes the market by application areas such as arthroscopy, ENT endoscopy, GI endoscopy, gynecology, laparoscopy, neurology, pulmonary endoscopy, and urology. The analysis covers both rigid and flexible endoscopes and lists the market opportunities by different end-user categories such as hospitals, day care and ambulatory centers, and stand-alone specialized clinics. Market opportunities are analyzed for 2 sets of endoscope repair market participants original equipment manufacturers (OEMs) and independent service organizations (ISOs). It also provides strategic insights for targeted growth opportunities for each set of participants. The US endoscope repair landscape will see stable pricing levels in the next 5 years, with a mild downward pressure, due to the increasing penetration of ISOs, which are expected to gain market share. However, OEMs will be the dominant participants in terms of both repair volume and value. While the overall endoscope repair market is driven by procedure volume and not as much by repair types and is application-agnostic, GI endoscopy, laparoscopy, and neurology are the target market for flexible endoscopes and are the largest revenue-generating segments. Repair probability is driven by manual cleaning, improper reprocessing using AER, usage frequency, and lifecycle extension. Damage to most endoscopes is driven by improper handling of endoscopes during procedures and not due to regular wear and tear. The study also covers current and forecast market size, as well as current and forecast ISO and OEM penetration in terms of revenue and repair volumes. It offers analysis of budget trends, key influencers, and decision makers in the repair vendor decisions of care providers. Detailed profiles of some key OEMs are provided, with a focus on their endoscope repair capabilities, with an analyst s perspective on OEMs strategic focus on enhancing their repair capabilities. The study also profiles key ISO endoscope repair vendors in the United States. It offers a matrix, comparing the repair capabilities of key OEMs in terms of indicators such as on-site service support, training and education, technology upgrade programs, repair exchange programs, and virtual support capabilities. It also offers comparison of key ISOs in the United States in terms of on-site service support, mobile support, training and education, repair exchange programs, and loaner programs offered by them. Key OEM competitors in the market include Olympus, KARL STORZ, Boston Scientific, Stryker, Fujifilm, B. Braun, Pentax, Smith & Nephew, Conmed Corporation, and Richard Wolf. The major ISOs functioning in the United States include Steris IMS, Mobile Instrument Service and Repair Inc., Prezio Health, Fibertech Medical USA, Total Scope Inc., ERS Repair, and Henry Schein, Inc. Key questions the study will answer include: What are the costs of endoscope repair across common damage areas? What are the different service models operating in the market? What are the future directions? What is the current and forecast market size of the US endoscope repair market in terms of revenue and repair volumes, as well as ISO and OEM penetration rates? Which are the aspects of vendor service that are valued the most by care providers? What are the unmet needs? What are the key growth opportunities for endoscope repair and maintenance vendors for future growth? Wed, 21 Jun 2017 00:00:00 +0100 eHealth Innovations in Western Europe http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297667379 Healthcare in Western Europe is changing radically as a result of varying demographics, rise of chronic diseases, and mounting financial pressure on health systems to control overall healthcare expenditure. Tue, 20 Jun 2017 00:00:00 +0100 Transformation and Growth Opportunities in the US Next-Generation Sequencing Informatics Market http://www.frost.com/prod/servlet/sublib/display-report.do?id=K190-01-00-00-00 Frost & Sullivan expects strong demand for commercial application-focused solutions to drive new investments in the development of tools and technologies, and will also result in consolidation of the US next-generation sequencing informatics market. Changing customer requirements and intense competition will drive the transformation. As companies look to develop end-to-end informatics solutions focused on end-use applications, Frost & Sullivan expects a significant growth in mergers, acquisitions, and partnerships. At the same time, given the growing applications of healthcare Big Data tools in genomics data interpretation, the market is expected to witness the entry of several healthcare information technology majors over the next 5 to 7 years. This study, from Frost & Sullivan s Life Science and Research Tools program, determines which customer segments will emerge as key opportunity areas through 2021. It identifies various opportunities across customer and market segments, determines unmet customer needs, and provides insights on approaches that can be taken by competitors to solve industry challenges. The report offers quantitative and qualitative assessments of revenue growth opportunities and calls to action across the pharmaceutical, academic lab, molecular diagnostics, and hospital lab spaces. It provides details about companies to watch, market drivers and restraints, and growth strategies for prospective market entrants. Key questions this study will answer: What are they opportunities that make this an attractive market with significant future revenue potential for companies? What are the key success factors that will help companies remain relevant and competitive in this crowded market? What do the current and prospective competitive landscapes look like? What approaches are players taking to counter competitive threats? What is the growth potential for NGS informatics across the different customer segments? What innovative approaches will replace current business models to overcome existing challenges? Tue, 20 Jun 2017 00:00:00 +0100 Growth Opportunities in the APAC IVD Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P97C-01-00-00-00 The study aims to analyze and forecast the Asia Pacific (APAC) in-vitro diagnostics (IVD) market outlook and technology trends for 2016. Research Scope: Key trends and opportunities in the IVD market, which has been segmented into 8 major divisions: o Immunochemistry o Self-monitoring Blood Glucose (SMBG) Meter o Hematology o Point-of-care Testing (POCT) o Tissue Diagnostics o Hemostasis o Clinical Microbiology o Molecular Diagnostics Regional trends in APAC; it covers China, India, Japan, Australia, South Korea, and member states of the Association of Southeast Asian Nations (ASEAN) The APAC IVD industry is undergoing major transformation. Paradigm shifts in the Asian healthcare ecosystem are driving the future of the IVD industry with stellar growth rates and rampant uptake of innovative technologies. Market penetration of molecular diagnostic (MDx) tests in infectious disease diagnosis, laboratory automation for high throughput operational efficiency, and digital pathology are three major themes that will impact the future of clinical pathology in Asia. The spurt in the number of private healthcare sectors and market shift towards quality care, private insurance, and high demand for medical tourism have led Asia to be on par with western counterparts in terms of availability and access to novel technologies. However, given the huge potential and market opportunities, there remain significant challenges in the complex market with preferential demands in Asian countries and fluidic regulatory and market access networks that pose significant challenges for operating companies. The APAC IVD industry, worth $ 14.44 billion in 2016, is expected to reach $19.64 billion in 2021 growing at a CAGR of 6.3%. In molecular diagnostics, infectious disease has the highest market share of 72.0%, followed by oncology (14.3%), genetic disorders (10.0%), and pharmacogenomics (3.7%). Digital innovations in the IVD industry, such as digital pathology, precision medicine, and health analytics are radically changing the care continuum in APAC. The IVD market is moving towards total laboratory automation from task-targeted automation. Although stand-alone automation systems are cost effective in clinical labs, multiple stakeholders in the healthcare ecosystems including physicians, payers, and administrators demand connected-pathology solutions. Key Questions This Study will Answer: 1. What is the current IVD market scenario in Asia? 2. What are the emerging segments in Asia? 3. What are the hot beds in Asia for investment in diagnostics? 4. What are the regional dynamics that impact the growth of the IVD industry? 5. What is the penetration of novel diagnostic solutions across the care continuum pathway? Mon, 19 Jun 2017 00:00:00 +0100 Recent Advances in Healthcare Diagnostics and Therapies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4B-00-00 This edition of the Genetic Technology TOE depicts new life sciences trends across diagnostics and therapeutics. Clinical trial results for several indications using antibody therapy are illustrated. Innovations in engineered 3D heart tissue and metabolome analyses for drug testing are also depicted. The corresponding clinical trial scenario is exhibited, along with the corresponding industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Clinical trials, antibody therapy, migraine, engineering 3D heart tissue, drug testing, metabolome, comprehensive diagnostics Fri, 16 Jun 2017 00:00:00 +0100 A Snapshot of Innovations in the MedTech Industry http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-12-00-00 The latest issue of the Medical Devices TOE profiles technologies for treatment of esophageal atresia, surgical skin closure, a jaw fracture device, a laparoscopic positioning system, a closed-loop spinal cord stimulation system, a camera-enabled handheld arthroscope, and a bioactive glass bone glass substitute. The issue also profiles future growth initiatives of technology developers. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Esophageal atresia, skin closure, jaw fracture, laparoscopic surgery, spinal cord stimulator, chronic pain, arthroscope, lumbar spinal stenosis, bone substitute Fri, 16 Jun 2017 00:00:00 +0100 Is Healthcare in America a Right or Commodity? A European View of the Healthcare Debate in America http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297650927 Many Americans have a fundamental, albeit misguided belief about a capitalist economy. The belief is success is solely a measure of hard work and intellect, while failure is the mark of diminished intelligence, criminality, or a desire to live off government perceived entitlements. Tue, 13 Jun 2017 00:00:00 +0100 Global Healthcare Data Analytics Companies-To-Action, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1E6-01-00-00-00 Healthcare data analytics refers to information technology (IT) solutions and services that mine structured and unstructured digital content generated by healthcare industry stakeholders with the goal of achieving a pre-defined outcome. The healthcare industry is experiencing a redefinition of value through the changing expectations of care quality, reimbursement models, and patient experience. To deliver new forms of value , industry stakeholders need a far more granular dissection of data and payers, providers, pharmaceuticals and medical technology companies are taking this move very seriously. To support these rapidly evolving stakeholders, data analytics vendors are bringing new and innovative solutions to the market that can help solve highly specific business issues around developing new solutions, revenue streams, operating models, and target customers. However, current solutions seem to have a rather niche scope, which creates obstacles for both data analytics companies rather complex and crowded market landscape consisting multiple solution segments and their healthcare industry customers. While data analytics vendors need to navigate a rather complex and crowded market landscape consisting of multiple solution segments, healthcare organizations need to invest in diverse vendors to meet their business goals. Future market success lies in providing meaningful analytics based on real-world data that accelerate R&D, enhance complete care pathways for specific therapeutic areas, and augment human thinking. Vendors need to expand their solutions across complete healthcare functions or therapeutic areas through appropriate partnerships and/or portfolio expansion. This creates opportunities for integration of different types of analytics solutions; integration of diverse healthcare stakeholders and datasets, and/or integration of diverse target market segments, such as providing solutions comprehensive platforms that support patients, providers, and payers. A complex vendor landscape creates opportunity for strategic partnerships amongst leading multinationals and small- and medium-sized businesses. At the same time, Industry Convergence opens up Blue Ocean markets where existing participants can provide new solutions, address evolving customer needs, and experiment with innovative business models. In such an environment, it becomes imperative for companies to have a clear view of the market landscape with a constant eye out for potential peers and competitors. Key parameters used for identifying appropriate industry partners include company size and growth, vision & goals, solution portfolio, market presence, and future plans. This research profiles vendors across diverse domains within Healthcare Data analytics to bring the most recent and successful and/or high-potential companies to light. Frost & Sullivan s focus has been to identify vendors who bring in the advantage purely in terms of analytics and not other components of data management and meaningful use. Key Questions this Study will Answer: What are the current growth opportunities in healthcare data analytics? What is the impact of the external industry environment on this market? Which are some unique companies that are introducing new and innovative solutions in the market? How do these companies intend to transform healthcare industry paradigms over the next five years? What is their action plan and potential for growth? What are some key success factors in the healthcare data analytics market? Tue, 13 Jun 2017 00:00:00 +0100 Recent Developments across Biotechnology Sector http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4A-00-00 This edition of the Genetic Technology TOE depicts trends across biotechnology. Opiod addiction tests that have been approved, companies developing companion diagnostics kits, novel genetic tests, and potential drug-based treatments are illustrated through the most recent innovations. The corresponding clinical trial scenario for CAR T Cell is depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Life sciences technologies, opioid addiction drug, immunotherapy, companion diagnostics, genetic markers, personalized skin care solutions, CAR T cell Fri, 9 Jun 2017 00:00:00 +0100 Recent Advances in Drugs for Mitochondrial Diseases http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-12-00-00 Mitochrondrial diseases arise when there is a malfunctioning mitochondria. These diseases are sometimes cause by genetic anomalies and can also be acquired hereditarily. While some mitocondrial disorders affect only a single organ such as Leber hereditary optic neuropathy (LHON), there are others that can result in problems across multiple organs. However, extensive research is taking place for treating these rare disease, with multiple starts up receiving funding for their efforts in gene therapy, cellular therapy, and small molecule therapeutics. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Mitochondrial disorder, mitochondria, small molecule therapeutics Fri, 9 Jun 2017 00:00:00 +0100 Internet of Medical Things, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1AB-01-00-00-00 Healthcare is one of the industries facing disruption by technological advances in the Internet of Things (IoT) space, and yet it is only partially aware of the advances, potential, and benefits. Almost 60% of healthcare organizations have already adopted healthcare IoT or Internet of Medical Things (IoMT), and realized cost savings, improved their profitability, visibility and customer experience. Indeed, IoMT serves the financial interests of healthcare industry stakeholders including investors, manufacturers, providers and physicians. It is well-suited to meet the needs of the transforming healthcare industry, by supporting the transition from disjointed care to coordinated care and reactive to proactive care-delivery approaches, for example. An estimated 4.5 billion IoMT devices existed in 2015, accounting for 30.3% of all IoT devices globally; this number is expected to grow to 20-30 billion IoMT devices by 2020. Capitalizing on this trend with the right applications for the right customers with the right partners and relevant business models is crucial for healthcare stakeholders to survive the fierce competition, which is supported by start-up companies and technology giants alike. With IoMT, a connected ecosystem of sensors and devices on and around the individual serve to capture and measure, identify, stratify risks, inform, make decisions and take actions. With that underlying principle, the IoMT market has five application areas. The On Body area covers wearable devices such as smart devices, peripherals, and even implants. The In Home environment includes digital/virtual assistants, activity monitors, and home medical devices. Within the Community segment, automated kiosks, emergency response intelligence and mobility are application areas. In the Clinic segment, handheld medical devices and care-coordination technologies as well as administrative support tools are areas where IoMT is making its mark. The In Hospital area benefits from IoMT use for real-time location services, patient/personnel flow tools and smart, connected equipment for better inventory management and resource utilization. This study covers the landscape of the Internet of Medical Things by application areas on body, in home, community, in clinic, and in hospital. For each application area, IoT use cases, vendor landscape of over 100 IoMT stakeholders, potential opportunities and challenges have been covered. Additionally, analysis on business model considerations for IoMT stakeholders, case studies, and future perspectives has also been provided. Key questions that this study will answer: What does the current IoMT market landscape look like? Which areas are being served, and by whom? What are the segment-specific challenges and opportunities for IoMT market incumbents and those considering entering the market? What strategies for success can be employed by stakeholders? What are the important business model considerations for IoMT stakeholders and new entrants? What are the future perspectives that IoMT industry stakeholders and new entrants should be aware of? Tue, 6 Jun 2017 00:00:00 +0100 Recent Advances across Healthcare Biomarkers http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-49-00-00 This edition of the Genetic Technology TOE depicts trends across healthcare biomarkers. Different biomarkers including blood-based proteomics and immuno-oncology biomarkers are profiled through recent innovations. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Blood-based proteomics, breast cancer detection, cancer immunotherapy, immuno-oncology biomarkers, drug resistance, fibromyalgia detection Fri, 2 Jun 2017 00:00:00 +0100 Growth Opportunities in the European Next-generation Sequencing Informatics Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD05-01-00-00-00 The cost of genomic sequencing has significantly declined in the recent past with the utilization of high-throughput sequencers creating opportunities for Next-generation Sequencing (NGS) informatics to develop genetic insights from the growing volume of sequencing data. As NGS technologies mature and the market stakeholders develop clarity on industry requirements, the market is expected to undergo significant transformation. Primary and secondary analyses are getting automated and commoditized with market growth being propelled by clinically focused tertiary analysis solutions. Support from government and R&D labs, launch of national-level genomic data collection initiatives, and expanding usage in the clinical space have provided impetus to the market in Europe. The NGS Informatics market has been segmented into 3 segments: secondary analysis, tertiary analysis and data storage. The European NGS Informatics market was worth $236.6 million in 2016 and is expected to reach $508.6 million by 2021 at a CAGR of 16.5%. Tertiary analysis represents the highest market share of 72%, followed by secondary analysis at 22% and data storage at 6%. The European NGS informatics is a competitive space with a handful global players and a large number of regional players vying for market share. Opportunities in NGS informatics market in Europe: As the industry matures, end users of NGS informatics services will look for focused and customized solutions. Customers expect seamless end-to-end genetic solutions in an easy-to-use format at competitive prices. Exacted NGS informatics is to be used for discovery and development in precision medicine, molecular diagnostics, and so on. Application of Big Data methodologies to handle the burgeoning genomic dataset and inclusion of novel data sources such as multi-omics and EMR/EHR data is expected. NGS informatics is likely to find application in novel areas such as agriculture/plant/animal biotechnology and in industries such as consumer products and food and nutrition. Europe is a key market in the global NGS informatics space with the presence of cutting-edge NGS technology infrastructure, a highly educated population receptive of NGS technologies and significant government support. UK, Germany, and France are likely to emerge as key markets. However, with a fragmented market and diverse regulatory and reimbursement rules across nations, NGS informatics companies are likely to face challenges in successful commercialization of their solutions. This study highlights the growing prominence of NGS informatics industry in Europe, growth opportunities, competitive dynamics, and a regional analysis of Europe. Key Questions this Study will Answer: 1. How is the market attractiveness for NGS service informatics over the years? 2. What are the factors driving the demand for NGS informatics? 3. Who will be the key users of NGS informatics in the future? 4. What will be the focal areas of application of informatics services? 5. What are the factors impacting informatics providers? 6. What are the key challenges being faced by stakeholders? 7. Which are the game-changing companies at work? 8. What are the strategic levers to stay on the growth trajectory? 9. How is the changing economic scenario affecting the regional market? 10. Which are the key markets in Europe? Wed, 31 May 2017 00:00:00 +0100 10 Ways Internet of Medical Things Is Revolutionizing Senior Care http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297607985 In 2000 about 10% of the world s population were aged 60 or over. By 2015 that had risen to 12%. United Nations projections indicate that will have increased to 16% by 2030, and jumped to 22% by 2050. Fri, 26 May 2017 00:00:00 +0100 Recent Advances in Life Science Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-48-00-00 This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across different technologies, including genetic testing for cancer, exosome technology capabilities, and gene delivery approaches. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cancer risk, genetic testing, gene delivery, telomerase reverse transcriptase, stem cell lines Fri, 26 May 2017 00:00:00 +0100 Innovations in Endoscopy, EEG, Multimodal Imaging, and Cloud-based Image Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-14-00-00 The latest issue of Medical and Diagnostic Imaging TOE profiles a motley of innovations from the medical imaging space. These include the use of cloud platform and artificial intelligence algorithms for medical image analysis, a novel handheld endoscopic tool for the diagnosis of cancerous tissues, a compact camera for molecular imaging, and a hand-held EEG device for neural imaging. These innovations cover a wide spread of the imaging industry, and are typically in early development stage. While their proof-of-concept has been established, their widespread clinical adoption will be realized in the next 18 to 24 months. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Multimodal imaging, healthcare cloud, medical imaging informatics, 3D holographic displays, molecular imaging Fri, 26 May 2017 00:00:00 +0100 The Future of Patient Monitoring Impact of Mobile Cardiac Telemetry http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297605579 Roman Legions over 2,000 years ago made provisions for their infantry wounded in battle to be treated and monitored by care givers. At the time, simple observation and palpitation for a heartbeat was the extent of available clinical resources. Thu, 25 May 2017 00:00:00 +0100 Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K18C-01-00-00-00 The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of care testing (POCT) and liquid biopsy continue to attract investment opportunities from private equity and venture capitalists. The new government in the United States aims to provide a retail-like experience for healthcare services. As a result, innovative and clinically vetted direct to consumer (DTC) diagnostic testing services are expected to thrive. Partnerships with non-healthcare (HC) companies are expected to empower core diagnostic companies with artificial intelligence (AI) and big data capabilities are on the rise. Given these market trends, it is important to understand the market dynamics to remain competitive and successful in the IVD market in the United States of America. Research Scope: The key objectives of this growth opportunity study are to track the changes in the IVD market landscape in the United States for 2016-2021. The study aims to identify growth segments and disruptive companies to invest into. Further, the study provides an in-depth revenue and market share analysis of over 8 segments within the IVD landscape: POCT, tissue diagnostics, self-monitoring blood glucose meter (SMBG), hemostasis, hematology, clinical chemistry, microbiology, immunochemistry, and molecular diagnostics. The study highlights industry challenges, growth drivers, restraints, competitive developments, mergers and acquisition, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA), identifies transforming business models, and makes strategic recommendations to understand the dynamics of the US IVD market. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies and transforming business models, as well as strategic recommendations. Key Questions this Study will Answer: 1. What are some of the current issues that concern the US IVD industry? How would these impact the different stakeholders in the healthcare landscape? 2. Which are the major segments of growth and why should you invest in them? 3. How to identify partners outside the conventional IVD realm? 4. How can big data support the growth of the IVD industry? 5. What are some of the newer products to watch in 2017 and beyond? 6. Which companies are categorized as early disruptors in this space? Who are the possible candidates to acquire, invest in, and help grow your business? Tue, 23 May 2017 00:00:00 +0100 Innovations in Medical Device Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-11-00-00 The latest issue of the Medical Devices TOE profiles innovations across the innovation ecosystem and the breadth of the medical devices industry. These include innovations from university research labs, start-up companies, corporations and findings from clinical trials. The innovations come from diverse fields such as super-capacitors for implantable medical devices, 3D printed components for implants, injectable sensors for physiological monitoring, and augmented reality device for therapy. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Implantable medical devices, 3D printing, biosensors, neuromodulation Fri, 19 May 2017 00:00:00 +0100 Recent Advances in Cancer Immunotherapy and Tumor Profiling Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-47-00-00 Cancer immunotherapy and cancer profiling are key areas of growth across the healthcare community. These vital areas will define the future of how cancer is screened, diagnosed, managed, and monitored. With technology areas such as exosome technology being implemented in profiling tumors, a paradigm shift can be brought about in how cancer is detected. Early detection of cancer will enable it to be controlled and managed in a better manner. New strides have been made in the development of immunological therapeutics, thereby increasing the treatment possibilities for patients suffering with certain types of hard to treat cancers. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cancer profiling, exosome technology, extracellular vesicles, liquid biopsy, cancer therapeutics, immunotherapy Fri, 19 May 2017 00:00:00 +0100 US Clinical Decision Support Systems Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K163-01-00-00-00 Clinical Decision Support Systems and services have evolved from being an authoritative content market dominated by large Scientific, Medical, and Technical (STM) publishers to being a dynamic and evolving connected infrastructure that includes digital workflow, electronic health record (EHR), and a variety of point-of-care solutions. While clinical guidelines and protocols remain critical components of this market, the landscape now includes a mix of suppliers, including medical device manufacturers and cloud-based clinical surveillance tools. The overall CDSS market is expected to grow by a CAGR of 8.9% from 2016 to 2021. Point-of-care solutions will be a key area of market growth. EHR providers will strive to become the hub of a CDSS, either by integrating access to CDS sources from within the EHR or through links to sources that have partnering agreements with the EHR provider. Workflow solutions, such as Computerized Physician Order Entry Systems (CPOE), documentation and scheduling sources, in addition to charge capture capabilities are also important in the market. One exciting aspect of CDSS in the digital era is the growing volume of patient data derived from medical devices, and monitoring systems, both from within the hospital and remotely. Additional scores of data signal expanded opportunities for new data analytics systems and models. This growing cache of medical data should support breakthroughs in Population Health Management Systems. Perhaps, the most exciting segment within CDSS is clinical surveillance systems that are capable of spotting serious patient-related issues with even more reliability than expert medical staffers. These systems use advanced data models to spot, at the point-of-care, nuances among the complex mix of medical indicators that may signal the prelude for a serious-yet-preventable medical event. This report also covers an array of established and new industry participants offering services in the segments covered, such as Wolters Kluwer, Zynx Health, The American College of Radiology, athenahealth, Philips, Elsevier, HCA, Premier, IBM (Truven), Inovalon, eClinical Works, Epic, Meditech, Perigen, Isabel Health, Motive Medical Intelligence, and many others. Major questions this research will answer include: What are the major trends impacting the CDSS space? What are the major participants across CDSS and by market segment? What are the competitive dynamics of the CDSS market? What is the revenue outlook for CDSS and the major segments? What are the strategic imperatives and calls to action that will define growth and success within the CDSS market over the next five years? Frost & Sullivan predicts that CDSS will evolve to become advanced predictive analytic tools, based on input from a patient s history, next-generation sequencing, and patient-generated data. Complex machine learning algorithms, artificial intelligence, and cognitive computing will influence advances in CDSS over the coming decades. The report also predicts the growing importance for patients to have access to CDSS from reliable medical-grade sources. Thu, 18 May 2017 00:00:00 +0100 The Proposed American Health Care Act Impact on the Medical Device Industry http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297587303 On Wednesday, May 3, 2017 the United States House of Representatives proposed two amendments to the failed AHCA expecting to break the gridlock among Republicans to enable passage of a Republican healthcare bill to repeal and replace the ACA. Wed, 17 May 2017 00:00:00 +0100 Point-of-Care Solutions as a Key Area of Growth Opportunity in Clinical Decision Support Systems (CDSS) http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297584784 Clinical Decision Support Systems (CDSS) represent a critical component of healthcare vital to improving patient care and outcomes in a variety of ways. The concept of clinical decision support (CDS) has been important for many years. Tue, 16 May 2017 00:00:00 +0100 Bioinformatics and Advanced Analytics Powering Drug Discovery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-11-00-00 Personalized medicine has brought forth a new avenue for innovation. Currently, genomics is being accelerated into extensive use across drug development and drug discovery. The capability of genomics has brought about the resurgence of biomarkers that could effective patient stratification, ensuring the right drugs are developed to treat a specific type of disease. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Precision oncology, genomics, personalized medicine, glycoproteomics, circulating tumor cells, biomarkers, ALS, malaria Fri, 12 May 2017 00:00:00 +0100 Advancements across Health and Wellness http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-46-00-00 Innovations across health and wellness are improving the quality of diagnosis and prevention. Currently, preventative solutions are gaining a wider acceptance, while solutions like probiotics that supplement the nutrition needs of an individual are important for ensuring a healthy population. However, the current state of diagnosis needs to ensure that physicians get results from blood tests and simple diagnostic tests quicker. Steady steps are being taken to develop point of care diagnostics that will yield the results that most physicians require. These technologies can be stationed in all clinics, hospitals, and even remote villages with limited infrastructure for large scale diagnostics equipment. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Probiotics, nutrition, sepsis, biomarkers, sepsis diagnosis, gut health, oral health, oral cavity Fri, 12 May 2017 00:00:00 +0100 Therapeutic Breakthroughs in Multiple Sclerosis http://www.frost.com/prod/servlet/sublib/display-report.do?id=D835-00-1C-00-00 This edition of the Future Tech TOE primarily encompasses comprehensive analyses of key emerging therapies across multiple sclerosis (MS). The service also includes treatment overviews, clinical pipeline analysis, IP and funding analysis, and emerging innovations across MS therapies. Furthermore, the research features the impact of key technology drivers and restraints for the global MS therapeutic industry, while providing an overview of the emerging technological landscape for MS treatments. The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Multiple sclerosis, stem cell therapy, Ocrevus, Ocrelizumab, neurodegenerative disease, Natalizumab, Alemtuzumab, Fingolimod, Teriflunomide, autologous hematopoietic stem cell transplantation (AHSCT), monoclonal antibody treatment Fri, 12 May 2017 00:00:00 +0100 Respondents Show Significant Interest in Developing Clinical NGS-based Tests for Infectious Disease Testing Applications http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297567506 Next-generation sequencing and the use of genomics in diagnosis and treatment have generated many headlines in recent years, both for advancements on the research front, as well as in the development of diagnostics and pharmaceutical products that leverage genomics in oncology and other early-adopting fields. Fri, 5 May 2017 00:00:00 +0100 Diagnostic and Therapeutic Developments across Global Healthcare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-45-00-00 This Genetic Technology TOE depicts recent diagnostic and therapeutic advances across the global healthcare industry. Clinical trial scenario for monoclonal antibody therapies for migraine are also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Diagnostics, therapeutics, epigenetic diagnostics, molecular diagnostics, urologic cancer, lung cancer, expanded collaboration, migraine antibody platform, 3D scaffold, organ transplants, mobile app, diabetes management Fri, 5 May 2017 00:00:00 +0100 Top 9 Predictions for Global Healthcare 2017 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297564501 Public and political pressure on controlling surging drug prices globally will compel health authorities to take transparency measures around drugs pricing, especially for some of the expensive diabetes and cholesterol medicines Thu, 4 May 2017 00:00:00 +0100 How All of Medicine will become Precision Medicine: 5 Evolving Trends to Watch http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297562372 Precision medicine promises a paradigm shift in the care delivery arena. It is a new model of medicine with new disease taxonomy. In future, precision medicine will be enabled by data both from direct and indirect sources, probing the deepest mysteries affecting individual health and well-being. Wed, 3 May 2017 00:00:00 +0100 Why Digital Solutions Are Poised to Disrupt the Behavioral Healthcare Industry http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297557874 The lack of mental health parity in care delivery has been spoken of several times before, but probably little has been done globally to treat this serious cause of disability. Tue, 2 May 2017 00:00:00 +0100 3D Printing Medical Devices http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297558858 3D printing, a relatively new wave of manufacturing technology has made huge impact on healthcare industry globally by providing customization to a growing number of healthcare applications and bringing down the cost. Tue, 2 May 2017 00:00:00 +0100 Top Technologies in Medical Devices & Imaging, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7C8-01-00-00-00 TechVision's Medical Devices and Imaging technology cluster's flagship research service profiles ten cutting-edge medical technologies that are expected to have a huge impact on the healthcare industry in the next two years. Each of technologies that have been profiled here represent billions of dollars in market potential, and have a rich track record of R&D funding, intellectual property (IP) activity and a vibrant innovation ecosystem. Each of the technology profiles covers the following: Brief technology snapshot, breadth of applications, key innovations and innovators, five-year market potential, recent funding and business deals, important market factors aiding and hindering growth. This research service aims to act as a guide for innovation-focused organizations who seek to learn about the medical technologies that will fuel growth in the next few years. This list includes technologies that are just seeing the light of commercialization, as well as those technologies that are already in the market, but are expected to make an impact through wide-spread adoption. This research service is a product of a year-long scout of the MedTech industry and other adjacent innovation clusters. This report aims to provide a snapshot of the ten technologies, service as a strategic guide to innovators and senior management, helping companies in innovation planning and decision-making. Fri, 28 Apr 2017 00:00:00 +0100 End-user and Decision-maker Survey of Southeast Asian PACS Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P96D-01-00-00-00 The research service provides an in-depth analysis of the Picture Archiving and Communication System (PACS) market across six Southeast Asian countries with a focus on end-user and radiology decision-maker needs, challenges, and vendor preferences. The study provides opportunity analysis, vendor landscape, and evolving technology and business model trends between 2016 and 2021. Key Target Audience: The study is an excellent starting point for both multinational imaging informatics leaders as well as local vendors aiming to enter and expand penetration in Southeast Asia. The research service is also relevant for healthcare providers, as it highlights the key challenges faced by radiologists and emerging technologies that can help improve the efficiency and service quality of the radiology department. Research Scope: At a compound annual growth rate (CAGR) of 6.8% between 2016 and 2021, the Southeast Asian PACS market represents a rapidly maturing sector with revenue opportunities for both new and renewal solutions. The market stands divided between two distinct types of consumers: the experienced PACS decision makers and the novices. Organizations that are currently investing in their second or third generation of PACS are well aware of the workflow issues that may arise due to an under-planned implementation. These experienced PACS decision makers are turning toward vendor-neutral solutions and heavily emphasize the need for better interoperability in the radiology department. Furthermore, several hospitals, especially in the Philippines and Vietnam, will be investing in their first PACS solution and are thus, more budget conscious and also want to take baby steps toward digitalization. Indonesia and Malaysia are the fastest growing countries in the region, followed closely by Thailand. Singapore represents a progressive market that is ready for sophisticated solutions including advanced viewers, imaging analytics, and decision support tools. The study provides further insights into target hospital segments and ideal channels for market penetration across each of these countries. A key finding of the study is that many PACS end users and decision makers feel that vendors do not collaborate enough with hospitals while building the solution. Healthcare providers would like to work with vendors who truly understand individual hospital workflows and then design solutions. While not so much interested in modularity, providers would certainly want their imaging IT solutions to be scalable, keeping in mind the fast pace of hospital infrastructure and services expansion in the region. Southeast Asian countries covered in this study: Indonesia Malaysia The Philippines Singapore Thailand Vietnam Key Questions This Study Will Answer: What is the market opportunity for PACS in Southeast Asia? Which countries and hospital segments represent opportunity hotspots for PACS? What are the unmet needs of target hospital segments and what are some vendor strategies for addressing these needs? How are vendors driving market entry and penetration? How will technological advancement fuel market growth, especially business model innovation? How will the competitive landscape evolve over the next five years? Fri, 28 Apr 2017 00:00:00 +0100 Top Technologies in Sensors and Instrumentation, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7C2-01-00-00-00 The technology and innovation research service covers the top 10 sensor and instrumentation technologies that will have highest impact in the near- to medium-term Key technologies in the sensor and instrumentation cluster were evaluated to arrive at the top 10 technologies for 2017. The technologies were selected after critical evaluation of an exhaustive list of technologies using TechVision's proprietary selection methodology. The research service assesses technologies from various aspects such as nature of disruption, key technology drivers, market potential, patents, funding, applications and megatrends impacted. The top 10 technologies covered in this research service are Biosensors, Touchless Sensing, Smart Haptics, ADAS, Electronic Skin/e-skin, Energy Harvesting, Drones, Robotics Sensors, Electronic Nose and Nanosensors. Fri, 28 Apr 2017 00:00:00 +0100 Innovations in Biomedical Imaging http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-13-00-00 The latest issue of Medical and Diagnostic Imaging TOE profiles innovations in biomedical imaging. Some of the profiles covered include magnetic resonance imaging (MRI) for targeted drug delivery, computerized blood flow simulation with MRI scans, next-generation contrast agents, upper extremity MRI modality, tablet-controlled computed tomography scanners, transoral robot-assisted high-resolution microendoscopic imaging, and newer applications of Raman spectroscopy. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Targeted drug delivery, computerized blood flow simulation, upper extremity imaging, tablet-controlled computer tomography, robotic microendoscopic imaging, Raman spectroscopy Fri, 28 Apr 2017 00:00:00 +0100 Advancements across Skin Testing Sector http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-44-00-00 This Genetic Technology TOE depicts trends across the skin testing sector. Technology profiles for skin mimicking, tissue models, in vitro testing and tissue engineering approaches are presented. Clinical trials scenario for skin irritation testing is depicted along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cosmetic testing, skin patch test, skin sensitization, skin products, tissue engineering, epidermal models, skin irritation testing Fri, 28 Apr 2017 00:00:00 +0100 Top Technologies in Health and Wellness, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7C9-01-00-00-00 This strategic research service, Health & Wellness Top 10 Technologies, depicts the current landscape and the new trends in a series of developments associated with innovations in Precision Oncology, Biobetters,Human Microbiomics, Immune Engineering, Cancer/Tumor Profiling, Cellular Therapeutics, Tissue Engineering, Molecular Diagnostics, Gene Editing and Predictive Biomarkers. Techvision's professionals have monitored, gathered, and analyzed numerous emerging and disruptive technologies selecting this top 10 technologies, by contacting an extensive network of innovators, technology developers, financial institutions, technologists and researchers, among other players in the ecosystem, with the aim to provide your company or institution with a notable intelligence work that can help you build and implement strong growth strategies by leverage disruptive technologies and emerging innovations. Fri, 28 Apr 2017 00:00:00 +0100 Emerging Woundcare Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7AF-01-00-00-00 Wounds are known to have major impact on patient function and quality of life and may be even life-threatening. To address the range of complex wound care industry challenges, there is an influx of technologies such as sensor technology, information and communication technology, 3D printing technology or the advanced stem cells technology. Integration of these technologies into the wound care product can help improve care and patient outcomes, and give it a competitive advantage over the traditional wound care products. Thu, 27 Apr 2017 00:00:00 +0100